GSA CONTRACT #: GS-35F-0448WTITLE: "CANCER MOONSHOT BIOBANK ONLINE CATALOG."NON-SEVERABLE (BASE PERIOD) / T&M TYPE BPA CALL.BPA CALL BASE PERIOD OF

美国国家癌症研究所（NCI）的癌症登月计划旨在加速由专家组成的“蓝带小组”（BRP）确定的关键战略领域的癌症研究。BRP建议的核心内容包括通过解决关键的科学问题来加速癌症研究的进展。还包括需要全国范围内的患者参与研究，代表美国人口的多样性。NCI启动了癌症登月生物样本库，通过收集和分发用于关键研究工作的生物标本来加速研究。生物样本库将与1000多名接受标准治疗的癌症患者合作，进行纵向生物标本收集。根据BRP的建议，癌症患者将从美国医疗机构的不同参与者群体中招募到研究中。生物标本将分发给合格的科学家，以加速研究进展。生物样本库项目将与Leidos Biomedical， Inc. （LBR）密切合作，与指定为生物样本来源站点（BSS）的社区医院和其他医疗机构合作，吸引并同意符合条件的参与者，收集生物样本和相关临床数据；与中央生物标本核心资源（BCR）合作，支持生物标本收集、处理和储存活动，并进行病理质量控制；与LBR的分子表征（MoCha）实验室合作，进行临床肿瘤分子表征分析，并将结果反馈给患者及其医生；并通过在线目录系统向研究人员提供生物标本和相关数据，以加速癌症研究的进展。临床结果的反馈、专门的患者和提供者参与（PPE）网站、电子知情同意、当地参与者参与项目以及嵌入式伦理、法律和社会问题子研究将共同支持患者和提供者参与该计划。

The National Cancer Institute’s (NCI) Cancer Moonshot Program is intended to accelerate cancer research in key strategic areas that were identified through a “Blue Ribbon Panel” (BRP) of experts. Core elements of the BRP recommendations include accelerating progress in cancer research by addressing critical scientific questions. Also included is the need for nationwide participation in research by patients that represent the diversity of the U.S. population. NCI has initiated the Cancer Moonshot Biobank to accelerate research through the collection and distribution of biospecimens for key research efforts. The Biobank will engage with over one thousand cancer patients, being treated with standard-of-care therapies, for longitudinal biospecimen collection. In keeping with the BRP recommendations, the cancer patients will be enrolled into the study from a diverse participant population engaged at medical institutions throughout the U.S. The biospecimens will be distributed to qualified scientists to accelerate research progress. The Biobank program, working closely with Leidos Biomedical, Inc. (LBR), will partner with community hospitals and other medical institutions, designated as Biospecimen Source Sites (BSS), to engage and consent eligible participants and collect biospecimens and associated clinical data; work with a central Biospecimen Core Resource (BCR) to support biospecimen collection, processing and storage activities and perform pathology quality control; work with LBR’s Molecular Characterization (MoCha) lab to perform clinical tumor molecular characterization assays and return results to patients and their physicians; and make the biospecimens and associated data available through an online catalog system to researchers to accelerate cancer research progress. Return of clinical results, a dedicated Patient and Provider Engagement (PPE) website, electronic informed consent, local participant engagement projects, and an embedded ethical, legal and social issues sub-study will together support patient and provider engagement in the program.